References
1. Ghersi D, Willson ML, Chan MMK, Simes J, Donoghue E, Wilcken N. Taxane-containing regimens for metastatic breast cancer. The Cochrane database of systematic reviews . 2015;2015(6):CD003366-CD003366. doi:10.1002/14651858.CD003366.pub3
2. Clamp AR, James EC, McNeish IA, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. The Lancet . 2019;394(10214):2084-2095. doi:10.1016/s0140-6736(19)32259-7
3. Masters GA, Temin S, Azzoli CG, et al. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.Journal of Clinical Oncology . 2015;33(30):3488-3515. doi:10.1200/jco.2015.62.1342
4. Lu Z, Zhang X, Liu W, et al. A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer . 2018;21(5):782-791. doi:10.1007/s10120-018-0809-y
5. Rowinsky EK. Paclitaxel pharmacology and other tumor types. Semin Oncol . Dec 1997;24(6 Suppl 19):S19-1-s19-12.
6. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet . 2010;376(9747):1147-1154. doi:10.1016/s0140-6736(10)61389-x
7. Lee H, Park S, Kang JE, Lee HM, Kim SA, Rhie SJ. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis. Scientific Reports . 2020;10(1)doi:10.1038/s41598-019-57380-0
8. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.Journal of the American Chemical Society . 1971;93(9):2325-2327. doi:10.1021/ja00738a045
9. Walsh V, Goodman J. The billion dollar molecule: Taxol in historical and theoretical perspective.Clio Med . 2002;66:245-67. doi:10.1163/9789004333499_013
10. Joerger M. Treatment regimens of classical and newer taxanes. Cancer Chemother Pharmacol . Feb 2016;77(2):221-33. doi:10.1007/s00280-015-2893-6
11. Schrag D, Hershman DL, Basch E. Oncology Practice During the COVID-19 Pandemic. JAMA . 2020;323(20):2005-2006. doi:10.1001/jama.2020.6236
12. Gosain R, Abdou Y, Singh A, Rana N, Puzanov I, Ernstoff MS. COVID-19 and Cancer: a Comprehensive Review.Curr Oncol Rep . May 8 2020;22(5):53. doi:10.1007/s11912-020-00934-7
13. Jibodh RA, Lagas JS, Nuijen B, Beijnen JH, Schellens JH. Taxanes: old drugs, new oral formulations.Eur J Pharmacol . Oct 5 2013;717(1-3):40-6. doi:10.1016/j.ejphar.2013.02.058
14. Schellens JHM, Malingré MM, Kruijtzer CMF, et al. Modulation of oral bioavailability of anticancer drugs: from mouse to man. 2000;12(2):103-110. doi:10.1016/s0928-0987(00)00153-6
15. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science . Sep 23 1983;221(4617):1285-8. doi:10.1126/science.6137059
16. Helgason HH, Kruijtzer CMF, Huitema ADR, et al. Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. 2006;95(7):794-800. doi:10.1038/sj.bjc.6603332
17. van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res . Oct 1998;4(10):2293-7.
18. Malingré MM, Terwogt JM, Beijnen JH, et al. Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol . Jun 2000;18(12):2468-75. doi:10.1200/jco.2000.18.12.2468
19. Paek IB, Ji HY, Kim MS, Lee G, Lee HS. Metabolism of a new P-glycoprotein inhibitor HM-30181 in rats using liquid chromatography/electrospray mass spectrometry. 2006;20(9):1457-1462. doi:10.1002/rcm.2468
20. Paek IB, Ji HY, Kim MS, Lee GS, Lee HS. Simultaneous determination of paclitaxel and a new P-glycoprotein inhibitor HM-30181 in rat plasma by liquid chromatography with tandem mass spectrometry. 2006;29(5):628-634. doi:10.1002/jssc.200500368
21. Kim T-E, Gu N, Yoon SH, et al. Tolerability and Pharmacokinetics of a New P-Glycoprotein Inhibitor, HM30181, in Healthy Korean Male Volunteers: Single- and Multiple-Dose Randomized, Placebo-Controlled Studies. 2012;34(2):482-494. doi:10.1016/j.clinthera.2012.01.003
22. Lee HJ, Heo D-S, Cho J-Y, et al. A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer. 2014;46(3):234-242. doi:10.4143/crt.2014.46.3.234
23. Lee KW, Lee KH, Zang DY, et al. Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer. 2015;20(8):896-897. doi:10.1634/theoncologist.2015-0202
24. Jackson CGCA, Bayston KF, McLaren BR, et al. An open label, randomised cross-over bioavailability study of oral paclitaxel (oraxol) compared to intravenous paclitaxel 80mg/m2.Journal of Clinical Oncology . 2016;34(15_suppl):2569-2569. doi:10.1200/JCO.2016.34.15_suppl.2569
25. Umanzor G, Cutler DL, Barrios FJ, et al. Abstract GS6-01: Oral paclitaxel with encequidar: The first orally administered paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: A phase III clinical study in metastatic breast cancer. Cancer Research . 2020;80(4 Supplement):GS6-01. doi:10.1158/1538-7445.SABCS19-GS6-01